10.1371/journal.pone.0190638.g004
Yoo Jin Choi
Yoo Jin
Choi
Seong-Joon Park
Seong-Joon
Park
You-Soo Park
You-Soo
Park
Hee Sung Park
Hee Sung
Park
Kwang Mo Yang
Kwang Mo
Yang
Kyu Heo
Kyu
Heo
Characterization of the EpCAM peptide-specific CTL responses against HepG2 CSCs.
Public Library of Science
2018
peptide-T 2 binding assay
EpCAM peptides
anti-tumor immunity
HLA-A 2 molecules
antigen
CTL
CSC marker
MHC
cytotoxic T lymphocytes
HCC
CD 44
T cell stimulation
breast cancer
EpCAM peptide-primed dendritic cell vaccination
TAA
hepatocellular carcinoma cells Cancer stem-like cells
DC
2018-01-03 18:38:33
Figure
https://plos.figshare.com/articles/figure/Characterization_of_the_EpCAM_peptide-specific_CTL_responses_against_HepG2_CSCs_/5755047
<p>(A) IFN-γ release by antigen-specific CTLs stimulated by antigens. Naïve T cells stimulated by co-culturing with tumor antigen-pulsed DCs were analyzed by ELISA for their production of IFN-γ. (B and C) Results from a cytotoxicity assay of CD8<sup>+</sup> T cells activated by tumor antigen-pulsed DCs. Different DCs were co-cultured at a ratio of 1:5 with lymphocytes for 5 days. The non-adherent cells were collected and counted as effector cells. The effector cells were co-cultured with the EpCAM positive (B) and EpCAM negative (C) HepG2 cells at different ratios for 6 h at 37°C in a 5% CO<sub>2</sub> incubator. The data are expressed as the mean±SD, and significant differences between the treated groups were detected using ANOVA followed by the Dunnett’s test. <sup>#</sup> <i>p</i><0.05 compared with the DCs or DC-CTLs, and * <i>p</i><0.05 compared with the TL-CTLs.</p>